Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

This study is open-label, multi-center, prospective study, which targets childhood patients with relapsed acute lymphostatic leukemia including bone marrow recurrence. Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for relapsed acute lymphoblastic leukemia in children and adolescents.

Trial Details

NCT ID
NCT05827549
Phase
PHASE2
Sponsor
Ho Joon Im
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • Reinduction(4weeks)
  • Cosolodation 1st(3weeks)
  • Consolidation 2nd(3weeks)
  • Blinatumomab 1st(High Risk Group)_4 Weeks
  • Blinatumomab 2nd (High Risk Group)_4 Weeks
  • Blinatumomab-Salvage 1st (Very High Risk Group)_4 Weeks
Locations (sample)
  • Hwasun, South Korea|35.06125,126.98746
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Patients \<= 1 year and \>22 years of age at the time of relapse will be eligible
  • Participants must have a histologic diagnosis of acute lymphoblastic leukemia:
  • B-ALL: Precursor B-cell acute lymphoblastic leukemia
  • T-ALL: Precursor T-cell acute lymphoblastic leukemia

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →